

**Clinical Trials Summary for out of hours  
Important Reference**

<b>Study Title</b>	ARCUS PEAK 1
<b>Study Summary</b>	A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma
<b>Principal Investigator</b>	Dr Natalie Charnley
<b>Research Team responsible for the Study</b>	Oncology Research Team RN Rashmi Madan CTSO Aaisha Khan
<b>Drug therapy</b>	<p><b>Arm A (Experimental Arm)</b> Doses and administration of Casdatifan (INVESTIGATIONAL PRODUCT) and Cabozantinib will be administered using a 28-day cycle:</p> <ul style="list-style-type: none"> <li>• Casdatifan (INVESTIGATIONAL PRODUCT) is administered orally at 100 mg once a day (QD) of each cycle.</li> <li>• Cabozantinib administered orally at 60 mg QD of each cycle.</li> </ul> <p><b>Arm B (Comparator Arm)</b> Doses and administration of placebo and Cabozantinib will be administered using a 28-day cycle:</p> <ul style="list-style-type: none"> <li>• Placebo administered orally QD of each cycle.</li> <li>• Cabozantinib administered orally at 60 mg QD of each cycle.</li> </ul>
<b>ACTION to take if a patient calls this</b>	<b>8AM TO 5PM: 01772522136, 5PM TO 8AM OUT OF HOURS - Contact Chemo Helpline</b>

<b>hotline/present at ED</b>	Ext- 3205 – who will contact PI or Sub PI who can then follow unblinding process, if required.
------------------------------	--